Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

Presentation ACC 2017

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Presenter: Magnus Ohman

March 27, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

Presentation ACC 2017

iFR vs FFR-guided Coronary Intervention – iFR-SWEDEHEART

Presenter: Matthias Götberg

March 20, 2017

Presentation ACC 2017

Randomised Trial of FFR-guided Complete Revascularization versus Infarct Artery only Treatment in Multivessel STEMI Patients

Presenter: Pieter Smits

March 20, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

L.A. McKeown

March 19, 2017

Presentation ACC 2017

iFR vs FFR for Guiding Coronary Revascularization – DEFINE-FLAIR

Presenter: Justin E Davies

March 19, 2017

Presentation ACC 2017

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Presenter: Stephen G. Ellis

March 19, 2017

Presentation ACC 2017

The RAD-MATRIX Study

Presenter: Alessandro Sciahbasi

March 19, 2017

News Conference News ACC 2017

Radiation Exposure Greater for Radial vs Femoral PCI, RAD-MATRIX Dosimeter Study Confirms

L.A. McKeown

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

Todd Neale

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Todd Neale

March 18, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

L.A. McKeown

March 09, 2017

News Conference News ACC 2016

DANAMI3: Deferred Stenting, Ischemic Postconditioning No Help in STEMI

Todd Neale

April 04, 2016

Advertisement

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

iFR vs FFR-guided Coronary Intervention – iFR-SWEDEHEART

Randomised Trial of FFR-guided Complete Revascularization versus Infarct Artery only Treatment in Multivessel STEMI Patients

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery

iFR vs FFR for Guiding Coronary Revascularization – DEFINE-FLAIR

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

The RAD-MATRIX Study

Radiation Exposure Greater for Radial vs Femoral PCI, RAD-MATRIX Dosimeter Study Confirms

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

DANAMI3: Deferred Stenting, Ischemic Postconditioning No Help in STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content